Clinical trial
Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT00125385 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00125385 |
|---|---|
| Title | Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF) |
| Official title | Phase I, Open-Label, Multi-Center, Single-Dose, Dose-Escalating, Safety, Tolerability and Pharmacokinetic of GC1008 in Patients With Idiopathic Pulmonary Fibrosis |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Idiopathic Pulmonary Fibrosis |
| Intervention type | Biological |
| Interventions | GC1008 |
| Enrollment | 25 |
| Start date | Jul 1, 2005 |
| Primary completion | Sep 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Aug 1, 2005 |
| Last update posted | Apr 13, 2015 |
| Countries | Belgium, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: